{
    "medicine_id": "4d7c5043836b39f392b3350db826dcb83233dc76",
    "platform_id": "DB12498",
    "metadata": {
        "name": "Poteligeo 4 mg 1mL Injection",
        "composition": "4 mg 1mL Mogamulizumab",
        "clinical_particulars": {
            "therapeutic_indications": "For the intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides MF or S\u00e9zary syndrome SS after at least one prior systemic therapy This approval provides a new treatment option for patients with MF and is the first FDA approval of a drug specifically for S\u00e9zary Syndrome FDA label",
            "contraindications": {
                "disease": "The most common adverse reactions reported in 20 of patients randomized to mogamulizumab were rash including drug eruption infusion related reactions fatigue diarrhea upper respiratory tract infection and musculoskeletal pain FDA label Due to various adverse effects related to this drug the adverse reactions have been categorized by organ system Because of the risk of serious fatal ADRs patients administered mogamulizumab should be carefully monitored A36743 Upper respiratory tract infection This may occur due to decreased immunity following the administration of this drug Monitor for signs of respiratory infection including fever cough and shortness of breath L4171 Dermatological Patients must contact their healthcare provider immediately if they experience a new or worsening skin rash Treatment should be temporarily interrupted for moderate or severe skin rashes and permanently discontinued for a life threatening rash Fatal and life threatening skin adverse reactions including Stevens Johnson syndrome SJS and toxic epidermal necrolysis TEN have occurred in recipients of mogamulizumab Rash drug eruption is one of the most common adverse reactions associated with mogamulizumab L4171 FDA label Infusion Reactions Patients must contact their healthcare provider immediately for signs or symptoms of infusion reactions Treatment should be suspended for any infusion reaction and permanently discontinued for any life threatening infusion reaction L4171 Infections Patients must contact their healthcare provider if they experience fever or other signs of infection Infections should be monitored and treated promptly L4171 Autoimmune Complications Immune mediated or possibly immune mediated reactions have included myositis myocarditis polymyositis hepatitis pneumonitis and a variant of Guillain Barr\u00e9 syndrome FDA label Patients must notify their healthcare provider of any history of autoimmune disease Treatment should be suspended or permanently discontinued as appropriate L4171 Fatal and life threatening immune mediated complications have been reported in recipients of this drug FDA label Musculoskeletal pain This drug may cause musculoskeletal pain FDA label A note on complications of allogeneic hematopoietic stem cell transplantation Patients must be aware of the possible risk of post transplant complications when taking this agent Patients should be monitored for severe acute graft versus host disease GVHD and steroid refractory GVHD Females of Reproductive Potential Females who are able to become pregnant should use an effective method of birth control during treatment with Poteligeo and for at least three months after the last dose L4171",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "This drug is a CC chemokine receptor 4 CCR4 antagonist It is a monoclonal antibody which blocks T cell proliferation which leads to malignancy A36739 A36758 CCR4 is a chemokine receptor that is preferentially expressed by Th2 and regulatory T Treg cells In response to its ligands CCL17 TARC and CCL22 MDC CCR4 promotes T cell migration to extranodal sites including the skin A36758",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00255",
                        "description": "Diethylstilbestrol may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00269",
                        "description": "Chlorotrianisene may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00286",
                        "description": "Conjugated estrogens may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00655",
                        "description": "Estrone may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00783",
                        "description": "Estradiol may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00890",
                        "description": "Dienestrol may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00977",
                        "description": "Ethinylestradiol may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB01357",
                        "description": "Mestranol may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB04573",
                        "description": "Estriol may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB04574",
                        "description": "Estrone sulfate may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB04575",
                        "description": "Quinestrol may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB07931",
                        "description": "Hexestrol may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09070",
                        "description": "Tibolone may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09317",
                        "description": "Synthetic Conjugated Estrogens A may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09318",
                        "description": "Synthetic Conjugated Estrogens B may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09369",
                        "description": "Polyestradiol phosphate may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09381",
                        "description": "Esterified estrogens may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11478",
                        "description": "Zeranol may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11674",
                        "description": "Equol may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12487",
                        "description": "Promestriene may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB13143",
                        "description": "Methallenestril may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB13386",
                        "description": "Epimestrol may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB13418",
                        "description": "Moxestrol may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB13952",
                        "description": "Estradiol acetate may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB13953",
                        "description": "Estradiol benzoate may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB13954",
                        "description": "Estradiol cypionate may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB13956",
                        "description": "Estradiol valerate may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB15334",
                        "description": "Biochanin A may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB15335",
                        "description": "Formononetin may increase the thrombogenic activities of Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00002",
                        "description": "The risk or severity of adverse effects can be increased when Cetuximab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00028",
                        "description": "The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00043",
                        "description": "The risk or severity of adverse effects can be increased when Omalizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00051",
                        "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00054",
                        "description": "The risk or severity of adverse effects can be increased when Abciximab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00056",
                        "description": "The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00057",
                        "description": "The risk or severity of adverse effects can be increased when Indium In 111 satumomab pendetide is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00065",
                        "description": "The risk or severity of adverse effects can be increased when Infliximab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00072",
                        "description": "The risk or severity of adverse effects can be increased when Trastuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00073",
                        "description": "The risk or severity of adverse effects can be increased when Rituximab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00074",
                        "description": "The risk or severity of adverse effects can be increased when Basiliximab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00075",
                        "description": "The risk or severity of adverse effects can be increased when Muromonab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00076",
                        "description": "The risk or severity of adverse effects can be increased when Digoxin Immune Fab Ovine is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00078",
                        "description": "The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00081",
                        "description": "The risk or severity of adverse effects can be increased when Tositumomab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00087",
                        "description": "The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00089",
                        "description": "The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00095",
                        "description": "The risk or severity of adverse effects can be increased when Efalizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00098",
                        "description": "The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin rabbit is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00108",
                        "description": "The risk or severity of adverse effects can be increased when Natalizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00110",
                        "description": "The risk or severity of adverse effects can be increased when Palivizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00111",
                        "description": "The risk or severity of adverse effects can be increased when Daclizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00112",
                        "description": "The risk or severity of adverse effects can be increased when Bevacizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB00113",
                        "description": "The risk or severity of adverse effects can be increased when Technetium Tc 99m arcitumomab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB01257",
                        "description": "The risk or severity of adverse effects can be increased when Eculizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB01269",
                        "description": "The risk or severity of adverse effects can be increased when Panitumumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB01270",
                        "description": "The risk or severity of adverse effects can be increased when Ranibizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB04901",
                        "description": "The risk or severity of adverse effects can be increased when Galiximab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB04949",
                        "description": "The risk or severity of adverse effects can be increased when Pexelizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB04956",
                        "description": "The risk or severity of adverse effects can be increased when Afelimomab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB04958",
                        "description": "The risk or severity of adverse effects can be increased when Epratuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB04962",
                        "description": "The risk or severity of adverse effects can be increased when Bectumomab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB04964",
                        "description": "The risk or severity of adverse effects can be increased when Oregovomab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB04988",
                        "description": "The risk or severity of adverse effects can be increased when IGN311 is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05006",
                        "description": "The risk or severity of adverse effects can be increased when Adecatumumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05097",
                        "description": "The risk or severity of adverse effects can be increased when Labetuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05101",
                        "description": "The risk or severity of adverse effects can be increased when Matuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05111",
                        "description": "The risk or severity of adverse effects can be increased when Fontolizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05136",
                        "description": "The risk or severity of adverse effects can be increased when Bavituximab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05139",
                        "description": "The risk or severity of adverse effects can be increased when CR002 is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05209",
                        "description": "The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05304",
                        "description": "The risk or severity of adverse effects can be increased when Girentuximab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05336",
                        "description": "The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05405",
                        "description": "The risk or severity of adverse effects can be increased when XTL 001 is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05437",
                        "description": "The risk or severity of adverse effects can be increased when NAV 1800 is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05459",
                        "description": "The risk or severity of adverse effects can be increased when Briakinumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05496",
                        "description": "The risk or severity of adverse effects can be increased when Otelixizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05545",
                        "description": "The risk or severity of adverse effects can be increased when AMG 108 is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05550",
                        "description": "The risk or severity of adverse effects can be increased when Iratumumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05555",
                        "description": "The risk or severity of adverse effects can be increased when Enokizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05578",
                        "description": "The risk or severity of adverse effects can be increased when Ramucirumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05595",
                        "description": "The risk or severity of adverse effects can be increased when Farletuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05656",
                        "description": "The risk or severity of adverse effects can be increased when Veltuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05679",
                        "description": "The risk or severity of adverse effects can be increased when Ustekinumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05773",
                        "description": "The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05793",
                        "description": "The risk or severity of adverse effects can be increased when PRO 542 is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05797",
                        "description": "The risk or severity of adverse effects can be increased when TNX 901 is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05889",
                        "description": "The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05892",
                        "description": "The risk or severity of adverse effects can be increased when RI 624 is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05915",
                        "description": "The risk or severity of adverse effects can be increased when MYO 029 is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05916",
                        "description": "The risk or severity of adverse effects can be increased when CT 011 is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05941",
                        "description": "The risk or severity of adverse effects can be increased when Leronlimab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB05996",
                        "description": "The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06043",
                        "description": "The risk or severity of adverse effects can be increased when Olaratumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06049",
                        "description": "The risk or severity of adverse effects can be increased when IPH 2101 is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06050",
                        "description": "The risk or severity of adverse effects can be increased when TB 402 is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06081",
                        "description": "The risk or severity of adverse effects can be increased when Caplacizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06101",
                        "description": "The risk or severity of adverse effects can be increased when IMC 1C11 is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06116",
                        "description": "The risk or severity of adverse effects can be increased when Eldelumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06162",
                        "description": "The risk or severity of adverse effects can be increased when Lumiliximab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06168",
                        "description": "The risk or severity of adverse effects can be increased when Canakinumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06186",
                        "description": "The risk or severity of adverse effects can be increased when Ipilimumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06192",
                        "description": "The risk or severity of adverse effects can be increased when Nimotuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06241",
                        "description": "The risk or severity of adverse effects can be increased when Clenoliximab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06273",
                        "description": "The risk or severity of adverse effects can be increased when Tocilizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06304",
                        "description": "The risk or severity of adverse effects can be increased when BIIB015 is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06305",
                        "description": "The risk or severity of adverse effects can be increased when Sonepcizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06310",
                        "description": "The risk or severity of adverse effects can be increased when Motavizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06317",
                        "description": "The risk or severity of adverse effects can be increased when Elotuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06318",
                        "description": "The risk or severity of adverse effects can be increased when AVE9633 is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06322",
                        "description": "The risk or severity of adverse effects can be increased when Carotuximab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06324",
                        "description": "The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06342",
                        "description": "The risk or severity of adverse effects can be increased when Coltuximab ravtansine is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06343",
                        "description": "The risk or severity of adverse effects can be increased when Teprotumumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06360",
                        "description": "The risk or severity of adverse effects can be increased when Lucatumumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06366",
                        "description": "The risk or severity of adverse effects can be increased when Pertuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06371",
                        "description": "The risk or severity of adverse effects can be increased when Siplizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06467",
                        "description": "The risk or severity of adverse effects can be increased when Apolizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06474",
                        "description": "The risk or severity of adverse effects can be increased when Sibrotuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06550",
                        "description": "The risk or severity of adverse effects can be increased when Bivatuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06557",
                        "description": "The risk or severity of adverse effects can be increased when Lerdelimumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06599",
                        "description": "The risk or severity of adverse effects can be increased when Lexatumumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06602",
                        "description": "The risk or severity of adverse effects can be increased when Reslizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06606",
                        "description": "The risk or severity of adverse effects can be increased when Teplizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06607",
                        "description": "The risk or severity of adverse effects can be increased when Catumaxomab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06612",
                        "description": "The risk or severity of adverse effects can be increased when Mepolizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06643",
                        "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06647",
                        "description": "The risk or severity of adverse effects can be increased when Volociximab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06650",
                        "description": "The risk or severity of adverse effects can be increased when Ofatumumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB06674",
                        "description": "The risk or severity of adverse effects can be increased when Golimumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB08870",
                        "description": "The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB08879",
                        "description": "The risk or severity of adverse effects can be increased when Belimumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB08902",
                        "description": "The risk or severity of adverse effects can be increased when Raxibacumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB08904",
                        "description": "The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB08935",
                        "description": "The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09029",
                        "description": "The risk or severity of adverse effects can be increased when Secukinumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09033",
                        "description": "The risk or severity of adverse effects can be increased when Vedolizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09035",
                        "description": "The risk or severity of adverse effects can be increased when Nivolumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09036",
                        "description": "The risk or severity of adverse effects can be increased when Siltuximab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09037",
                        "description": "The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09045",
                        "description": "The risk or severity of adverse effects can be increased when Dulaglutide is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09052",
                        "description": "The risk or severity of adverse effects can be increased when Blinatumomab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09057",
                        "description": "The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09077",
                        "description": "The risk or severity of adverse effects can be increased when Dinutuximab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09105",
                        "description": "The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09264",
                        "description": "The risk or severity of adverse effects can be increased when Idarucizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09302",
                        "description": "The risk or severity of adverse effects can be increased when Alirocumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09303",
                        "description": "The risk or severity of adverse effects can be increased when Evolocumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09312",
                        "description": "The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin horse is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09331",
                        "description": "The risk or severity of adverse effects can be increased when Daratumumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB09559",
                        "description": "The risk or severity of adverse effects can be increased when Necitumumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11569",
                        "description": "The risk or severity of adverse effects can be increased when Ixekizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11580",
                        "description": "The risk or severity of adverse effects can be increased when Ravulizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11595",
                        "description": "The risk or severity of adverse effects can be increased when Atezolizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11604",
                        "description": "The risk or severity of adverse effects can be increased when Tetanus Immune Globulin is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11608",
                        "description": "The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11621",
                        "description": "The risk or severity of adverse effects can be increased when Human Varicella Zoster Immune Globulin is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11646",
                        "description": "The risk or severity of adverse effects can be increased when Conatumumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11657",
                        "description": "The risk or severity of adverse effects can be increased when Tabalumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11680",
                        "description": "The risk or severity of adverse effects can be increased when Ficlatuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11685",
                        "description": "The risk or severity of adverse effects can be increased when Figitumumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11714",
                        "description": "The risk or severity of adverse effects can be increased when Durvalumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11715",
                        "description": "The risk or severity of adverse effects can be increased when Bapineuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11731",
                        "description": "The risk or severity of adverse effects can be increased when Depatuxizumab mafodotin is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11746",
                        "description": "The risk or severity of adverse effects can be increased when Onartuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11756",
                        "description": "The risk or severity of adverse effects can be increased when Solanezumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11767",
                        "description": "The risk or severity of adverse effects can be increased when Sarilumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11771",
                        "description": "The risk or severity of adverse effects can be increased when Tremelimumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11776",
                        "description": "The risk or severity of adverse effects can be increased when Brodalumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11803",
                        "description": "The risk or severity of adverse effects can be increased when Sirukumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11826",
                        "description": "The risk or severity of adverse effects can be increased when Lampalizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11834",
                        "description": "The risk or severity of adverse effects can be increased when Guselkumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11840",
                        "description": "The risk or severity of adverse effects can be increased when Dalotuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11849",
                        "description": "The risk or severity of adverse effects can be increased when Emibetuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11850",
                        "description": "The risk or severity of adverse effects can be increased when Ublituximab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11856",
                        "description": "The risk or severity of adverse effects can be increased when Ligelizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11857",
                        "description": "The risk or severity of adverse effects can be increased when Seribantumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11862",
                        "description": "The risk or severity of adverse effects can be increased when Landogrozumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11866",
                        "description": "The risk or severity of adverse effects can be increased when Romosozumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11884",
                        "description": "The risk or severity of adverse effects can be increased when Vadastuximab Talirine is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11914",
                        "description": "The risk or severity of adverse effects can be increased when Lebrikizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11930",
                        "description": "The risk or severity of adverse effects can be increased when Varlilumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11945",
                        "description": "The risk or severity of adverse effects can be increased when Avelumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11959",
                        "description": "The risk or severity of adverse effects can be increased when Crenezumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11972",
                        "description": "The risk or severity of adverse effects can be increased when Rilotumumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11976",
                        "description": "The risk or severity of adverse effects can be increased when Anifrolumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB11988",
                        "description": "The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12023",
                        "description": "The risk or severity of adverse effects can be increased when Benralizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12034",
                        "description": "The risk or severity of adverse effects can be increased when Gantenerumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12053",
                        "description": "The risk or severity of adverse effects can be increased when Visilizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12077",
                        "description": "The risk or severity of adverse effects can be increased when Urelumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12089",
                        "description": "The risk or severity of adverse effects can be increased when Lorvotuzumab mertansine is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12090",
                        "description": "The risk or severity of adverse effects can be increased when Patritumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12102",
                        "description": "The risk or severity of adverse effects can be increased when Fulranumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12104",
                        "description": "The risk or severity of adverse effects can be increased when Tarextumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12118",
                        "description": "The risk or severity of adverse effects can be increased when Sotatercept is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12119",
                        "description": "The risk or severity of adverse effects can be increased when Gevokizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12142",
                        "description": "The risk or severity of adverse effects can be increased when Duligotuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12152",
                        "description": "The risk or severity of adverse effects can be increased when Simtuzumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12157",
                        "description": "The risk or severity of adverse effects can be increased when Fasinumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12159",
                        "description": "The risk or severity of adverse effects can be increased when Dupilumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12169",
                        "description": "The risk or severity of adverse effects can be increased when Tralokinumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12189",
                        "description": "The risk or severity of adverse effects can be increased when Etrolizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12202",
                        "description": "The risk or severity of adverse effects can be increased when Zalutumumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12205",
                        "description": "The risk or severity of adverse effects can be increased when Ganitumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12213",
                        "description": "The risk or severity of adverse effects can be increased when Etaracizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12240",
                        "description": "The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12246",
                        "description": "The risk or severity of adverse effects can be increased when Inclacumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12250",
                        "description": "The risk or severity of adverse effects can be increased when Cixutumumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12261",
                        "description": "The risk or severity of adverse effects can be increased when Ascrinvacumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12274",
                        "description": "The risk or severity of adverse effects can be increased when Aducanumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12281",
                        "description": "The risk or severity of adverse effects can be increased when Luspatercept is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12296",
                        "description": "The risk or severity of adverse effects can be increased when GS 5745 is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12317",
                        "description": "The risk or severity of adverse effects can be increased when Vanucizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12331",
                        "description": "The risk or severity of adverse effects can be increased when Labetuzumab govitecan is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12335",
                        "description": "The risk or severity of adverse effects can be increased when Tanezumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12342",
                        "description": "The risk or severity of adverse effects can be increased when Ensituximab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12344",
                        "description": "The risk or severity of adverse effects can be increased when Fezakinumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12363",
                        "description": "The risk or severity of adverse effects can be increased when Dusigitumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12396",
                        "description": "The risk or severity of adverse effects can be increased when Fresolimumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12413",
                        "description": "The risk or severity of adverse effects can be increased when Indusatumab vedotin is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12456",
                        "description": "The risk or severity of adverse effects can be increased when Bococizumab is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12489",
                        "description": "The risk or severity of adverse effects can be increased when Mirvetuximab Soravtansine is combined with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB12520",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Plozalizumab"
                    },
                    {
                        "drugbank-id": "DB12530",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Inebilizumab"
                    },
                    {
                        "drugbank-id": "DB12534",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Mavrilimumab"
                    },
                    {
                        "drugbank-id": "DB12560",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Blosozumab"
                    },
                    {
                        "drugbank-id": "DB12584",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Bimagrumab"
                    },
                    {
                        "drugbank-id": "DB12589",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Dacetuzumab"
                    },
                    {
                        "drugbank-id": "DB12609",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Tovetumab"
                    },
                    {
                        "drugbank-id": "DB12683",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Lumretuzumab"
                    },
                    {
                        "drugbank-id": "DB12698",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Ibalizumab"
                    },
                    {
                        "drugbank-id": "DB12701",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Intetumumab"
                    },
                    {
                        "drugbank-id": "DB12718",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Carlumab"
                    },
                    {
                        "drugbank-id": "DB12734",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Demcizumab"
                    },
                    {
                        "drugbank-id": "DB12773",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Sifalimumab"
                    },
                    {
                        "drugbank-id": "DB12775",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Abituzumab"
                    },
                    {
                        "drugbank-id": "DB12797",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Ecromeximab"
                    },
                    {
                        "drugbank-id": "DB12807",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Naptumomab Estafenatox"
                    },
                    {
                        "drugbank-id": "DB12815",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Crotedumab"
                    },
                    {
                        "drugbank-id": "DB12820",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Concizumab"
                    },
                    {
                        "drugbank-id": "DB12826",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Depatuxizumab"
                    },
                    {
                        "drugbank-id": "DB12844",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Rontalizumab"
                    },
                    {
                        "drugbank-id": "DB12845",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Amatuximab"
                    },
                    {
                        "drugbank-id": "DB12849",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Clazakizumab"
                    },
                    {
                        "drugbank-id": "DB12891",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Ozanezumab"
                    },
                    {
                        "drugbank-id": "DB12893",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Sacituzumab govitecan"
                    },
                    {
                        "drugbank-id": "DB12917",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Bimekizumab"
                    },
                    {
                        "drugbank-id": "DB12943",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Milatuzumab"
                    },
                    {
                        "drugbank-id": "DB12976",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Robatumumab"
                    },
                    {
                        "drugbank-id": "DB13017",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Rovalpituzumab Tesirine"
                    },
                    {
                        "drugbank-id": "DB13037",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Namilumab"
                    },
                    {
                        "drugbank-id": "DB13045",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Racotumomab"
                    },
                    {
                        "drugbank-id": "DB13073",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Tregalizumab"
                    },
                    {
                        "drugbank-id": "DB13127",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Olokizumab"
                    },
                    {
                        "drugbank-id": "DB13140",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Bezlotoxumab"
                    },
                    {
                        "drugbank-id": "DB13375",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Edrecolomab"
                    },
                    {
                        "drugbank-id": "DB13535",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Nebacumab"
                    },
                    {
                        "drugbank-id": "DB13886",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Human cytomegalovirus immune globulin"
                    },
                    {
                        "drugbank-id": "DB13923",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Emicizumab"
                    },
                    {
                        "drugbank-id": "DB13976",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Sulesomab"
                    },
                    {
                        "drugbank-id": "DB13979",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Besilesomab"
                    },
                    {
                        "drugbank-id": "DB14004",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Tildrakizumab"
                    },
                    {
                        "drugbank-id": "DB14012",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Burosumab"
                    },
                    {
                        "drugbank-id": "DB14039",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Erenumab"
                    },
                    {
                        "drugbank-id": "DB14040",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Eptinezumab"
                    },
                    {
                        "drugbank-id": "DB14041",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Fremanezumab"
                    },
                    {
                        "drugbank-id": "DB14042",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Galcanezumab"
                    },
                    {
                        "drugbank-id": "DB14211",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Fanolesomab"
                    },
                    {
                        "drugbank-id": "DB14580",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Lecanemab"
                    },
                    {
                        "drugbank-id": "DB14597",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Lanadelumab"
                    },
                    {
                        "drugbank-id": "DB14707",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Cemiplimab"
                    },
                    {
                        "drugbank-id": "DB14724",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Emapalumab"
                    },
                    {
                        "drugbank-id": "DB14762",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Risankizumab"
                    },
                    {
                        "drugbank-id": "DB14776",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Camrelizumab"
                    },
                    {
                        "drugbank-id": "DB14778",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Setrusumab"
                    },
                    {
                        "drugbank-id": "DB14784",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Gancotamab"
                    },
                    {
                        "drugbank-id": "DB14809",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Anetumab ravtansine"
                    },
                    {
                        "drugbank-id": "DB14811",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Isatuximab"
                    },
                    {
                        "drugbank-id": "DB14824",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Icrucumab"
                    },
                    {
                        "drugbank-id": "DB14843",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Codrituzumab"
                    },
                    {
                        "drugbank-id": "DB14864",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Brolucizumab"
                    },
                    {
                        "drugbank-id": "DB14871",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Xentuzumab"
                    },
                    {
                        "drugbank-id": "DB14877",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Lintuzumab"
                    },
                    {
                        "drugbank-id": "DB14891",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Vobarilizumab"
                    },
                    {
                        "drugbank-id": "DB14897",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Parsatuzumab"
                    },
                    {
                        "drugbank-id": "DB14905",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Emactuzumab"
                    },
                    {
                        "drugbank-id": "DB14907",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Bevacizumab zirconium Zr 89"
                    },
                    {
                        "drugbank-id": "DB14908",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Refanezumab"
                    },
                    {
                        "drugbank-id": "DB14919",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Rozanolixizumab"
                    },
                    {
                        "drugbank-id": "DB14947",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Bermekimab"
                    },
                    {
                        "drugbank-id": "DB14952",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Pamrevlumab"
                    },
                    {
                        "drugbank-id": "DB14959",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Opicinumab"
                    },
                    {
                        "drugbank-id": "DB14962",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Trastuzumab deruxtecan"
                    },
                    {
                        "drugbank-id": "DB14967",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Margetuximab"
                    },
                    {
                        "drugbank-id": "DB14988",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Dalantercept"
                    },
                    {
                        "drugbank-id": "DB14997",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Pateclizumab"
                    },
                    {
                        "drugbank-id": "DB15014",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Gremubamab"
                    },
                    {
                        "drugbank-id": "DB15022",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Apomab"
                    },
                    {
                        "drugbank-id": "DB15044",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Tafasitamab"
                    },
                    {
                        "drugbank-id": "DB15045",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Ipafricept"
                    },
                    {
                        "drugbank-id": "DB15076",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Abrilumab"
                    },
                    {
                        "drugbank-id": "DB15089",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Frovocimab"
                    },
                    {
                        "drugbank-id": "DB15090",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Tezepelumab"
                    },
                    {
                        "drugbank-id": "DB15101",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Tigatuzumab"
                    },
                    {
                        "drugbank-id": "DB15104",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Telisotuzumab vedotin"
                    },
                    {
                        "drugbank-id": "DB15113",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Utomilumab"
                    },
                    {
                        "drugbank-id": "DB15118",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Zolbetuximab"
                    },
                    {
                        "drugbank-id": "DB15135",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Ponezumab"
                    },
                    {
                        "drugbank-id": "DB15160",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Asunercept"
                    },
                    {
                        "drugbank-id": "DB15172",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Suvratoxumab"
                    },
                    {
                        "drugbank-id": "DB15225",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Mitazalimab"
                    },
                    {
                        "drugbank-id": "DB15252",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Nemolizumab"
                    },
                    {
                        "drugbank-id": "DB15253",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Bleselumab"
                    },
                    {
                        "drugbank-id": "DB15277",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Gedivumab"
                    },
                    {
                        "drugbank-id": "DB15336",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Valanafusp alfa"
                    },
                    {
                        "drugbank-id": "DB15349",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Sofituzumab vedotin"
                    },
                    {
                        "drugbank-id": "DB15354",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Evinacumab"
                    },
                    {
                        "drugbank-id": "DB15363",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Istiratumab"
                    },
                    {
                        "drugbank-id": "DB15383",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Pidilizumab"
                    },
                    {
                        "drugbank-id": "DB15397",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with GMA 161"
                    },
                    {
                        "drugbank-id": "DB15409",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Ladiratuzumab vedotin"
                    },
                    {
                        "drugbank-id": "DB15415",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Tomaralimab"
                    },
                    {
                        "drugbank-id": "DB15428",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Vesencumab"
                    },
                    {
                        "drugbank-id": "DB15432",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Pinatuzumab vedotin"
                    },
                    {
                        "drugbank-id": "DB15441",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Lulizumab pegol"
                    },
                    {
                        "drugbank-id": "DB15443",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Lorukafusp alfa"
                    },
                    {
                        "drugbank-id": "DB15453",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Naratuximab emtansine"
                    },
                    {
                        "drugbank-id": "DB15559",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Zenocutuzumab"
                    },
                    {
                        "drugbank-id": "DB15898",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Atoltivimab"
                    },
                    {
                        "drugbank-id": "DB15899",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Maftivimab"
                    },
                    {
                        "drugbank-id": "DB15900",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Odesivimab"
                    },
                    {
                        "drugbank-id": "DB15719",
                        "description": "The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Belantamab mafodotin"
                    },
                    {
                        "drugbank-id": "DB15595",
                        "description": "The therapeutic efficacy of Ebola Zaire vaccine live attenuated can be decreased when used in combination with Mogamulizumab"
                    },
                    {
                        "drugbank-id": "DB15258",
                        "description": "The therapeutic efficacy of Mogamulizumab can be decreased when used in combination with Imlifidase"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}